Oslo, Norway, 30 April 2025 - Zelluna (OSE: ZLNA), a company pioneering
allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells
for the treatment of cancer, invites to a webcast presentation of its first
quarter 2025 results, on Thursday, May 8, 2025.
The presentation can be followed as a live webcast accessed through a link on
www.zelluna.com at 09:00 CET on Thursday, May 8, 2025. The webcast presentation
will be available on the Zelluna website, and it will be possible to post
questions during the presentation through the webcast.
The report and presentation will be available on the company website from 07:00
CET the same day.
For further information, please see www.zelluna.com or contact:
For further information, please contact:
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
(https://www.globenewswire.com/Tracker?data=Z8lLmV-
B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup
zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)
Phone: +44 7720 687608
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
(https://www.globenewswire.com/Tracker?data=xw_BegYpiBk6hexlBFgOsk7tj2DC2GZ9wD-
xUL0RvSOAFKyBsXJCyN1-
yeYF_y4PiN7qNCFrqSFIFzf4Oy78pFiEzLGlsgS23tV0HELOjUoSe5eLjAVVxGWn_gS6AJdD)
Phone: +47 482 48632